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ABSTRACT
The synthesis of the transmembrane domain of 3 Amyloid Precursor Protein
was attempted. The peptide has a tendency to aggregate when being
synthesized on solid-phase, and has therefore never been synthesized.
Removable N-benzyl amide protecting groups were used to attempt to
prevent this aggregation. A portion of this peptide was synthesized with this
method.
NACP was overexpressed in E. coli. and purified. Preliminary structural
studies show that the 14.4 kDa protein is a random-coil, heat-stable protein.
The protein elutes from a gel filtration column at 55 kDa, but is a monomer
in solution. Affinity experiments and immunoprecipitation experiments
were performed in order to find an NACP-binding protein. A 96 kDa protein
was identified and will be analyzed for N-terminal amino acid sequencing.
Thesis Supervisor: Peter T. Lansbury, Jr.
Title: Associate Professor of Chemistry
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Chapter 1
Methods for the Synthesis of Hydrophobic Peptides
Introduction
Alzheimer's disease is a neurodegenerative disease characterized by the
presence of extracellular amyloid plaques, intracellular neurofibrillary tangles,
and cerebrovascular amyloid deposits'. Extracellular amyloid plaques consists
of dystrophic axons and dendrites surrounding a proteinaceous core of fibrils.
The core of the amyloid plaque consists of a 40 to 43 amino acid peptide called 3
amyloid (A3)2,3. AD is a fragment of a larger protein called 3 Amyloid Precursor
Protein (APP) 4. P3APP is a cell surface glycosylated transmembrane protein; it
consists of a extracellular domain (624 amino acids), a single transmembrane
region (24 residues), and a cytoplasmic domain (47 residues). A3 is derived from
the 28 amino acids immediately preceding the amino terminus of the
transmembrane (TM) domain of K3APP plus the first 12-15 residues of the TM
domain4 (Figure 1).
1 10 20 30
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMV
GGVVIATVIVITLVMLKKK
40 1 50
I,G,F
Figure 1. Sequence of K3APP containing AD (1 to 40-43) and transmembrane
domain (underlined). Numbering refers to AP sequence. Arrow shows site of
mutations in transmembrane domain.
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Although it is unclear what role AP has in causing Alzheimer's disease,
several mutations in the sequence of APP cause familial Alzheimer's diseases
The ability of these mutations in the sequence of PAPP to cause AD would seem
to signal the importance of amyloid in the pathology of AD. One set of
mutations (Figure 1) lies inside the TM domain, but outside the AP region. These
mutations do not affect the overall rate of cleavage to generate A3, but may affect
the site of cleavage, increasing the ratio of 1-42 to 1-406. In in vitro experiments,
[1-42 aggregates much faster than [1-40; increasing the concentration of 11-42,
in vivo, might cause nucleation and aggregation of amyloid7 . The mechanism of
cleavage of [3APP is unknown8 .
The mutations may cause a change in the site of cleavage by changing the
structure of the TM region in the lipid bilayer. One hypothesis is that the TM
domain is capable of dimerizing; the ability to dimerize may be related to the
production of amyloid. The mutations may change the structure of [APP by
altering the ability of the protein to dimerize. There are precedents in the
literature. Another transmembrane protein, glycophorin, has previously been
shown to form a dimer in lipid bilayers. Mutations L75 to V, A, or I and I76 to A
or F can eliminate dimerzation of glycophorin 9. Another example is the neu
proto-oncogene. A single point mutation (V664 to E) in the transmembrane
domain increases neu dimerizationl °.
In order to explore the possibility of [3APP dimerization, we are
attempting to synthesize the transmembrane region of [3APP along with the V46
to I, G, F mutants. By studying the behavior of the peptides in lipid bilayers or
micelles, we may be able to find differences between the wild type and mutants
that give clues to the mechanism of AP formation.
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Synthesis of Transmembrane Sequences
The synthesis of transmembrane domains of proteins is not a trivial
exercise. Extremely hydrophobic sequences have generally been difficult to
synthesize, being prone to aggregation on the resin supports. Aggregation of
difficult peptides on resin support has been shown to be often a result of beta-
sheet formation by the peptides. The N-terminal end of the growing peptide
then becomes sequestered in the aggregate, making chain extension sterically
impossible. One method to prevent aggregation is to place a 2-hydroxy-4-
methoxy benzyl group onto the nitrogen of every sixth amino acid in the
sequence'2. This removable protecting group is likely to be effective by
removing the hydrogen involved in beta sheet formation and by sterically
preventing the chains interacting.
OCH3 OCH3 OCH3
Hro R" .0 '\l deprotec
Fmoco4 R OR" Fmoco R 0 HO R O
NF Fr Ž R Froc YOH -R :
I Fmoc-j
Figure 2. General usage of benzyl amide protecting groups.
A major drawback to the use of the benzyl amide protecting groups is that it
involves the coupling of a secondary amine to the next amino acid in the
sequence (Figure 2). In addition, steric hindrance by the side chains of the
coupling partners is also likely to be a problem. Therefore, use of the amide
benzyl group should be limited to amino acids without beta branched side
chains2.
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Previous work in the group has been unsuccessful at synthesizing the TM
of 3APP, due to its tendency to aggregate on the resin. This work was repeated
using MBHA Rink Amide resin, under standard coupling conditions (3 eq amino
acid, 3 eq PyBOP, 5.3 eq DIEA, in DMF). Aggregation began by I47 (assayed by
concentration of accessible amine, as determined by quantitative ninhydrin
test'3) and was complete by T43 (accessible amine reduced to 6.6% of original
concentration).
The use of the benzyl amide protecting groups was attempted. As stated
previously, use of the protecting groups should be limited to amino acids
without beta branching. However, most of the amino acids in the C terminal end
of the TM region are beta branched. There are three potential sites of benzyl
amide attachment: L52, L49 and A42. Fmoc(N-2-hydroxy-4-methoxybenzyl)-
leucine 3 was synthesized from leucine (Scheme I). The N-benzyl leucine 2 was
synthesized by reacting leucine with 2-hydroxy-4-methoxy benzaldehyde in a
reductive amination 14 . N-benzyl leucine 2 was reacted with Fmoc-Cl in-
dioxane/aq Na2CO3 to yield 3. However, contrary to the literature12, only 3 was
formed, not the bis-Fmoc-N-benzyl derivitized amino acid 1.
o- .A
( OH
HN  OH OCi 3
I.KOHII
2.NaBH,
Fmoc-CI
dioxane/
10% aq Na2CO3
LK K K-esin ML K -Kesln
K K K -Resin a, Fmoc-Met
HATUJ H IATU O H3
I646 yield ax ylel -yield 2 3 4 chain extension I
VMLKKK-Resin 
IIATUJ
L V M L K K K - Resin
HOH
Scheme I. Synthesis of Fmoc(N-2-hydroxy-4-methoxybenzyl)leucine and its
coupling to the resin.
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3 was attached to KKK-Resin (3 eq, 6 eq HATU, 5.3 eq DIEA in DMF)
(Scheme I). According to the literature, HATU is a faster coupling agent than
PyBOP15. Fmoc-Met was then attached to resin-bound chain 4 (10 eq Fmoc-Met,
10 eq HATU, 5 eq DIEA in DMF) in 69% yield (as assayed by quantitative
ninhydrin). Repeated couplings did not increase yield. Chain extension (by
standard coupling methods) was still hindered by aggregation: after the
coupling of T43, the concentration of accessible amine was reduced to 14.5% of
the original concentration. Although the benzyl amide appears to have helped
prevent some aggregation, significant aggregation occurs before the next benzyl
amide (A42) can be used.
L49 is closer to A42 in the sequence. Unfortunately, the amino acid
following L49 is a sterically hindered T. Attempts to couple Fmoc-Thr-OH or
Fmoc-Thr(OtBu)-OH to resin-bound chain 5 (10 eq amino acid, 10 eq HATU, 5 eq
DIEA, in DMF) failed (Scheme I).
Low coupling yields on the resin could be avoided by performing the
difficult coupling of the secondary amine in solution, and attaching the resulting
dipeptide to the growing peptide chain (Scheme II). Boc-leucine was treated
with benzyl bromide in sodium carbonate/DMF to yield Boc-Leu-OBn 6.
0O H
poHŽI " HO 3NHCAc
o cDMrF/,NaC3 95
0 9% ied _ 95% yield
OCH3
NaBHCN/MeOH
SD yld
Fmoc' AF
DIEACI I12
F
NAN
-' N~'F no rxn
MLK K K- Resin
9 10 11 N AU
Scheme II. Synthesis of Fmoc-Thr(OtBu)-(N-2-hydroxy-4-methoxy-benzyl)-
leucine and its attempted coupling to the resin.
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The amino acid was deprotected with 3N HCl/ethyl acetate to yield Leu-
OBn 7. Reductive amination with 2-hydroxy-4-methoxy benzaldehyde yielded
N-benzyl derivitized Leu-OBn 8. Dipeptide 9 was formed from the coupling of 8
and the acid fluoride of Fmoc-Thr(OtBu). Use of HATU to perform this coupling
yielded no product. The dipeptide 9 was acylated to protect the alcohol, forming
dipeptide 10. The O-benzyl group was removed by catalytic hydrogenation (10%
Pd/C) to yield dipeptide 11.
Attempts to attach dipeptide 11 to the resin were unsuccessful. Use of
HATU as the coupling agent gave no yield. Dipeptide 11 was then reacted with
cyanuric fluoride (Scheme II). Very small amounts of acid fluoride were formed
(seen by TLC). The dipeptide 11 is most likely too sterically hindered to become
activated by the cyanuric fluoride.
The success of the coupling of 8 to the acid fluoride of Fmoc-Thr(OtBu)
caused a reevaluation of the possibility of coupling Thr to the secondary amine of
resin-bound peptide 5 (Scheme I). Preliminary results indicate that the coupling
of the acid fluoride of Fmoc-Thr(OtBu) to resin-bound peptide 5 (10 eq acid
fluoride, 5 eq DIEA, in DMF, 24 h; recoupled twice) proceeds to 90% yield (by
quantitative ninhydrin). Formation of the peptide TLVMLKKK has been
confirmed by PDMS (M+H = 960.1; calc = 960.31). It now remains to ascertain if
the benzyl amide is capable of preventing aggregation until the next benzyl-
amino acid (A42) is placed onto the resin.
abbreviations used: Boc = tert-butoxycarbonyl; Fmoc = 9-Fluorenylmethoxy-
carbonyl; PyBOP = Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexa-
fluorophosphate; DIEA = diethylisopropylamine; DMAP = 4-dimethylamino-
pyridine; HATU = 1-Hydroxy-7-azabenzotriazole; DMF = dimethylformamide;
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Rink Amide MBHA Resin = 4-(2',4'-Dimethoxyphenyl-Fmoc-aminomethyl)-
phenoxyacetamido-norleucyl-MBHA resin.
Experimental Section
Equipment, Materials, and Methods
All chemicals were purchased from Aldrich unless otherwise stated.
Protected amino acids were purchased from Novabiochem or Advanced
Chemtech. DIEA was purchased from Aldrich and distilled from ninhydrin
under reduced pressure. PyBOP and Rink Amide MBHA resin were purchased
from Novabiochem. HATU was obtained from Millipore. Cyanuric fluoride was
purchased from Fluka.
PDMS of compounds were measured on a Bio-Ion Plasma Desorption
Mass Spectrophotometer. 1H NMR were measured on a 250 MHz Bruker
instrument.
General Procedures for the Synthesis of Peptides
The Rink Amide MBHA resin was placed in a reaction vessel and swollen
with CH2C12. The following procedure (standard coupling procedure) was used
for the addition of each amino acid: 1) wash resin with DMF, 2) wash with 50 %
piperdine/DMF, 3) shake resin in 50% piperdine/DMF (15 min), 4) wash
alternately with DMF and CH2C12 (3x), 5) remove a small amount and perform
Kaiser test13 for free amine (test should be positive), 6) wash with DMF, 7) add
Fmoc-amino acid (3 eq, 0.1 M in DMF) and PyBOP (3 eq, 0.1 M in DMF), shake
resin for 30 s, 8) add DIEA (5.3 eq) and shake mixture for 1 h at RT, 9) wash
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alternately with DMF and CH2C12 (3x), 10) remove a small amount and perform
Kaiser test: if positive, repeat steps 6-9 until a negative result is obtained.
For unusual amino acid couplings, PyBOP was substituted with HATU (5-
10 eq), or an acid fluoride of an Fmoc-amino acid16 (10 eq) was substituted for
amino acid and coupling reagent.
N-(2-hydroxy-4-methoxybenzyl)leucine (2). Leucine (3 mmol, 303 mg)
was dissolved in a 0.5 M KOH solution (3 mmol, 6 mL). To this solution was
added 2-hydroxy-4-methoxy-benzaldehyde (456 mg, 3 mmol); enough ethanol
was added to solubilize the benzaldehyde. The reaction was stirred for 10 min,
then sodium borohydride (114 mg, 3 mmol) was added in H 20 (1 mL) over 45
minutes. The reaction was stirred for an extra 20 min, then acidified to pH 6.
Product crystallized, and the solution was cooled at 4C for 4 h, to complete
crystallization. The white precipitate (504 mg, 1.9 mmol, 64% yield) was
collected and used without further purification: 1H NMR (D20) 6 0.3 (dd, 6H),
1.2 (m, 3H), 3.2 (s, 3H), 3.3 (t, 1H), 3.7 (s, 2H), 6.0 (d, 2H), 6.7 (d, 1H).
Fmoc(N-2-hydroxy-4-methoxybenzyl)leucine (3). Dioxane (16 mL) was
added to a solution of 2 (300 mg, 1.1 mmol) in 10% sodium carbonate (30 mL).
Fmoc-Cl (710 mg, 2.7 mmol) was added in small amounts over 1 h. As each
portion was added, the Fmoc-Cl gradually dissolved, then a gel-like precipitate
formed. After stirring overnight, H20 was added, and the product was acidified
to pH 4 and extracted with ethyl acetate (3x). The organic layers were combined,
dried over magnesium sulfate, and concentrated by rotary evaporation. The
compound was purified by silica column chromatography (5% methanol/
chloroform). Yield = 58% (310 mg, 0.64 mmol): 1H NMR (CDC13) 6 0.9 (d, 6H),
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1.5 (t, 2H), 1.7 (m, 1H), 3.7 (s, 3H), 3.9 (s, 2H), 3.4 (t, 1H), 4.5 (d, 2H), 6.3 (dd, 1H),
6.5 (d, 1H), 6.8 (d, 1H); PDMS [M+H]+ = 489.0 (calc = 487.5)
N-(t-Butoxycarbonyl)-O-benzyl-leucine (6). N-tButoxycarbonylleucine
(3.7 g, 15 mmol) was suspended in DMF. Sodium bicarbonate (3.78 g, 45 mmol)
and benzyl bromide (2.7 mL, 22.5 mmol) were added, and the reaction was
stirred overnight. H 20 was added, and the product was extracted into ether (3x).
The organic layers were combined, washed with 1N HC1 (3x), and dried over
magnesium sulfate. The solution was concentrated by rotary evaporation and
chromatographed on silica gel (2.5% to 10% ethyl acetate/hexane). Yield of the
clear oil was 92% (4.42 g, 13.8 mmol): 1H NMR (CDC13) 8 0.9 (dd, 6H), 1.4 (s,
9H), 1.7 (m, 3H), 4.3 (t, 1H), 5.1 (d, 2H), 7.3 (s, 5H).
O-benzylleucine (7). Into 3N HCl/ethyl acetate (20 mL) was dissolved 6
(4.42 g, 13.8 mmol). The reaction was stirred for 2 h, after which the reaction was
brought to pH 10 with 3M NaOH. The product was extracted with ethyl acetate
(3x). The solution was dried over magnesium sulfate, and concentrated by rotary
evaporation to a clear oil (2.9 g, 13.1 mmol, 95% yield). The product was pure by
NMR, and used without further purification: 1H NMR (CDC13) 0.9 (dd, 6H),
1.7 (m, 3H), 4.0 (t, 1H), 5.1 (d, 2H), 7.3 (m, 5H).
N-(2-hydroxy-4-methoxy)-O-benzylleucine (8). Sodium cyanoboro-
hydride (6.24 mg, 10 mmol) and 7 (1.46 g, 6.6 mmol) were added to a solution of
N-hydroxy-4-methoxy-benzaldehyde (1 g, 6.6 mmol) in anhydrous methanol.
The pH was adjusted to 7 with glacial acetic acid. Hot molecular sieves were
added, and the reaction was purged with argon. The reaction was stirred under
argon for 48 h, during which the orange solution formed a precipitate. The
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reaction was quenched with a solution of saturated sodium bicarbonate, and
extracted with ether (3x). The organic layers were combined, dried over
magnesium sulfate, and concentrated. The residue was chromatographed twice
on silica gel (2.5% ethyl acetate/chloroform), to give a 50% yield (1.2 g, 3.3
mmol): 1H NMR (CDC13) 0.9 (dd, 6H), 1.5 (t, 1H), 1.75 (m, 1H), 3.4 (t, 1H), 3.75
(s, 3H), 3.8 (dd, 2H, J=75 Hz), 5.2 (d, 2H), 6.3 (dd, 1H), 6.5 (d, 1H), 6.8 (d, 1H), 7.4
(s, 5H).
N-Fmoc-(O-t-butyl)-threonine-N-(2-hydroxy-4-methoxy-benzaldehyde)-
O-benzyl-leucine (9). N-Fmoc-(O-t-butyl)-threonine (250 mg, 630 !~mol) was
dissolved in methylene chloride. Cyanuric fluoride (54 p1, 630 [tmol) and
pyridine (76 l1, 945 pmol) were added to the solution; the solution was stirred for
3 h. Ice water was added, and the organic layer was retained. The organic layer
was reduced by rotary evaporation. The acid fluoride was redissolved in
methylene chloride, and added to 120 mg of 8 (336 mol) in methylene chloride.
A 10% solution of sodium bicarbonate (1.6 mL) was quickly added. The reaction
was stirred overnight. The aqueous and organic layer were separated, and the
organic layer was reduced by rotary evaporation. The reaction was
chromatographed on silica gel (5% ethyl acetate/methylene chloride), but was
not completely purified. The product (90 mg) was too difficult to purify, and
was used without further purification: PDMS [M+H] + = 737.5 (calc = 736.9).
N-Fmoc-(O-t-butyl)-threonine-N-(2-O-acyl-4-methoxy-benzaldehyde)-O-
benzyl-leucine (10). The impure dipeptide 9 (90 mg) was dissolved in methylene
chloride and treated with acetic anhydride (60l1, 0.6 mmol), DIEA (102 l, 0.6
mmol), and a catalytic amount of DMAP. After 30 min, the reaction was washed
with saturated sodium bicarbonate (lx) and with 1 N HC1 (lx). The organic layer
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was dried over magnesium sulfate, concentrated, and chromatographed on silica
gel (5% ethyl acetate/methylene chloride). 55 mg (71 pmol, 21% total yield from
8) was isolated: 1H NMR (CDC1 3 ) 6 0.9 (dd, 6H, J = 25 Hz), 1.0 (d, 3H), 1.2 (s,
9H), 1.7 (m, 2H), 2.0 (m, 1H), 2.2 (s, 3H), 3.7 (s, 3H), 4.0-4.4 (m, 5H), 4.7 (m, 1H),
5.1-5.4 (m, 3H), 6.5 (m, 3H), 7.3 (s, 5H), 7.3-7.8 (m, 9H); PDMS [M+H] + = 780.1
(calc = 778.9).
N-Fmoc-(O-t-butyl)-threonine-N-(2-O-acyl-4-methoxy-benzaldehyde)-
leucine (11). Dipeptide 10 (55 mg, 71 imol) was dissolved in ethanol containing
a few drops of ethyl acetate and 1 drop of glacial acetic acid. A catalytic amount
of Pd/C was added and the reaction was purged with H2. After 3 h under H2,
the Pd/C was filtered and rinsed with ethyl acetate. The filtrate was reduced
with the addition of cyclohexane to yield pure white crystals (36 mg, 52 gtmol,
74% yield): 1H NMR (CDC1 3) 6 0.73 (dd, 6H, J = 18, 42 Hz), 1.09 (s, 3H), 1.16 (s,
9H), 1.5 (m, 2H), 1.8 (m, 1H), 2.25 (s, 3H), 3.6 (s, 3H), 3.8 (d, 1H), 3.9 (t, 1H), 4.2 (t,
2H), 4.4-4.6 (m, 5H), 6.7 (m, 2H), 6.9 (d, 1H), 7.3 (m, 5H), 7.7 (dd, 4H, J = 8.8, 42
Hz).
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Chapter 2
Structural and Functional Studies of NACP
Introduction
The major constituent of amyloid plaques in Alzheimer's disease is the AD
protein. NAC (non-AP component of AD amyloid), a peptide of at least 35 amino
acids in length, has also been determined to be an intrinsic component of amyloid.
The core of amyloid plaques may consist of up to 10% of NAC1. Immunohisto-
chemical studies have shown that other proteins, such as al-antichymotrypsin 2 ,
apolipoprotein E3, and many others, have been found to be associated with the core
of the amyloid plaque. NAC, however, is unique in that it has been copurified from
the SDS-insoluble fraction of amyloid plaques.
NAC is a fragment of NACP (NAC-precursor) which is a 140 amino acid
protein, with an expected molecular weight of 14,460. NACP purified from human
brain tissue has a molecular mass of 14,681, indicating that native NACP may have a
post-translational modification 4 . The amino-terminal amino acid of NACP is
unamenable to Edman degradation, and is therefore possibly modified. A
myristoylation (MW 211) may be indicated. There are no known signal sequences,
glycosylation sites, or phosphorylation motifs in the NACP sequence. However,
there is evidence that a highly homologous protein, bovine phosphoneuroprotein
14 (PNP14), is phosphorylated 5 .
NACP, also called synuclein, is highly homologous to Torpedo synuclein6 ,
rat synuclein 1,2, and 37, bovine phosphoneuroprotein 14 (PNP-14)5, canary synel-
fin8 , and human synuclein 4. There are two major isoforms in this family,
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differing in their C-termini. NACP, canary synelfin, and rat synuclein 1 share the
same acidic C-terminus; Human f3 synuclein and PNP-14 do not contain the NAC
sequence (Figure 1).
10 20 30 40 50 60 70
Human NACP MDVFMKGLSK AKEGWAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGWH GVATVAEKTK EQVTNVGGAV
Human D Syn M T E R Q S ASHL
Rat Syn I T
Canary Syn T E R Q T S
80 90 100 110 120 130 140
Human NACP VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMP--VDP DNEAYEMPSE G -- YQDYEPEA
Human 0 Syn FS N L REEF PTDLKPEEVA QEAAEE LIEPLMEP GE Y DPPQEE E
Rat Syn 1 N M G Y ES
Canary Syn N L A Q FL MVNNTGAA P E
Figure 1. Sequence of the various homologous forms of NACP; NAC is underlined.
The full sequence for NACP is shown; only different amino acids were shown for [3
synuclein, rat synuclein 1, and canary synelfin.
All forms of synuclein share a very similar N-terminus, containing a KTKEGV
motif, which occurs 5-6 times, within an 11 amino acid periodicity. It has been
suggested that this stretch of the protein forms an amphipathic helix capable of
associating with lipids8 .
The synucleins are primarily expressed in nervous tissue, and are found in
relatively small amounts in the other organs of the body 1,6,9. Immunohistochem-
istry studies show that rat synuclein expression is highest in the pyramidal cell layer
of the hippocampus 7 , which is a major site of AD caused neurodegeneration: the
process of amyloid deposition begins along the projections of the pyramidal neurons
within the hippocampus and parahippocampal structures °0 . NACP has been found
to be most enriched in the telencephalon, which includes the hippocampus' and
cerebral cortexl.
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NACP is an intracellular protein, localized to the presynaptic terminal l l .
Although there has been speculation that NACP is a synaptic vesicle associated
proteins, NACP exists mostly as a soluble protein, and it is unclear if NACP is
associated with lipid membranes8 .
We are interested in the relationship between NACP and Alzheimer's
disease. NAC in vitro forms ordered fibrils, which can be classified as amyloid. 12
Similar to the in vitro aggregation of 1-40, the aggregation of NAC was found to be
nucleation dependent and could be seeded with preformed NAC fibrils. NAC
amyloid fibrils were able to seed the aggregation of 1-40; fibrils made of 1-40 were
also able to seed the aggregation of NAC.
It is possible that, in vivo, accumulated NAC aggregates seed the aggregation
of 1-40, causing the neurodegeneration associated with Alzheimer's disease.
Alternatively, 1-40 may seed the aggregation of NAC, and the loss of NACP may be
the cause of the disease.
The function of NACP may well be related to memory and learning: the
rnRNA of NACP is upregulated in canaries during a critical period of song
learning8 . Other than its immunohistochemical location, and involvement in
canary learning, little else is known about NACP. This lab is currently involved
with studying NACP and peptides from NACP, with the hope that these studies will
lead to insight about its relationship to neurological diseases. We describe, here,
research on the structure and function of NACP.
Purification and Properties of NACP
A pRK172 plasmid containing the NACP expression sequence4 was obtained
from Michel Goedert. The plasmid was transformed into BL21(DE3) competent
cells, and overexpressed. The bacteria were lysed in a french press, and centrifuged.
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The supernatant was treated with streptomycin sulfate to precipitate the DNA, and
then boiled at 100'C for 5 min. Previous studies4 ,13 had indicated that NACP stayed
soluble after heat treatment, while most other proteins denatured and precipitated.
Final purification was performed by Paul Weinreb and was achieved by gel
filtration.
Consistent with previous observations4 6, recombinant NACP migrates as a 19
kDa protein in SDS-polyacrylamide gels. This behavior is attributed to the highly
acidic nature of the C-terminus4 , which affects binding of SDS to the protein.
The CD of NACP (Paul Weinreb, unpublished results) indicated that this
preparation of NACP lacked secondary structure. The heat treatment, however,
may have denatured the protein, and it was thus necessary to purify the protein
without having first boiled it.
NACP was overexpressed in bacteria, which were lysed and treated with
streptomycin sulfate. Ammonium sulfate was added to 46.6% saturation. The
pellet was redissolved in lysis buffer and loaded onto an S-300 size-exclusion
column. Although the protein is 14.4 kDa, it eluted at approximately 55 kDa. The
final purification step was a CL-6B DEAE Sepharose column, in which the protein
eluted at approximately 200 mM NaCl. The fractions were dialyzed against distilled
water and the protein was quick frozen in dry ice-acetone and lyophilized.
We were interested in the possibility that synuclein could be eluting from the
size exclusion column as an oligomer. Nakajo, et al. found that PNP-14 eluted at 57
kDa by gel filtration; they interpreted this to mean that PNP-14 exists as a tetramer in
saline solution at neutral pH. In our hands, purified boiled NACP, however, also
eluted at 55 kDa when run on the S-300.
Ferguson plots of boiled and unboiled NACP showed that the protein is likely
to be a monomer, not an oligomer (Figure 2). In the electrophoresis of proteins in a
native gel, there is a linear relationship between Kr (the slope of a plot of logio
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relative mobility vs gel concentration for any particular protein) and the molecular
mass of native proteins14. By constructing a plot of Kr vs molecular weight for a
series of known proteins, the molecular weight of an unknown protein can be
determined from a series of native gels.
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Figure 2. Ferguson Plot (Kr vs MW) of insulin, BSA, and pepsin. NACP (Kr = -.061)
plots to an approximate MW of 20,000.
The accuracy of Ferguson plots are highly dependent upon the similarity in shape
and hydrodynamic radius between the protein of interest, and protein standards.
We, however, needed only a rough approximation of the size of NACP, and
therefore chose readily available proteins as our standards.
CD's of the boiled and unboiled NACP were identical (Figure 3). Recom-
binant NACP is random coil. Although we were initially surprised that NACP was
a heat stable random coil protein, there are many other proteins which have these
same characteristics (tau15 , chromogranin A'6, several phosphatase inhibitors T17 18 ,
and others). None are enzymes; this is consistent with the amino acid sequence of
NACP: a protein containing such an extensive amino acid repeat would most likely
be a structural protein or binding protein, not an enzyme.
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Figure 3. CD of boiled vs. unboiled NACP (courtesy of Paul Weinreb).
Affinity Chromatography
We are interested in understanding the relationship between Alzheimer's
disease, amyloid, and NACP. We believe that a significant step would be taken if
the function of NACP were known. Towards this end, we have attempted to isolate
binding proteins for NACP via affinity chromatography.
Affinity chromatography is a fairly standard technique used to isolate binding
proteins for a particular ligand 19. In general, a ligand is affixed to a solid support
(usually Sepharose 4B), and a mixture is passed over the beads. A binding protein
for the ligand will be selectively retained on the column; the protein can be desorbed
from the column after unbound material has been washed away. The ligand
should have a Kd for the binding protein in the range of 10-4 to 10-8 in free
solution 19; a limitation of this technique is that a low affinity binding protein to
NACP will not be identified.
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Currently, many affinity columns are generated through the use of GST-
fusion proteins, or biotin-strepavidin systems. Covalent attachment of the ligand to
the column, however, is the traditional way of making a column, and there have
been many successes2
Proteins are usually covalently attached to Sepharose 4B by primary amino
groups or thiol groups. If neither is available, a protein may be attached by carboxyl
groups. NACP contains no cysteines; it, however, has many lysines. Cyanogen
bromide (CNBr) activated Sepharose 4B is a commercially available product
(Pharmacia Biotech) for convenient attachment of primary amino groups to
Sepharose (Figure 4). There is, however, the possibility of ligand leakage, via
nucleophilic attack on the isourea group. Multipoint attachment of the ligand to
the Sepharose is therefore advisable. NACP has many lysines by which multipoint
attachment may be achieved.
OH oH
CN- =CN 2N-p nd
CNBr Acivaed Sepbtas 4B
H,N-liand
Acivaed CH-Sepaose 4B
Figure 4. Structure of CNBr activated Sepharose 4B and Activated CH-Sepharose 4B,
and their attachment to ligands.
Multipoint attachment, however, may cause problems if the binding region
of NACP is blocked from interacting with the binding protein. It may, therefore, be
useful to work with beads containing a low concentration of NACP.
Steric hindrance can also be a problem when a protein is held too closely to
the surface of the bead for its binding site to be accessible. It is common to employ
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spacer arms; a drawback to the use of spacer arms is that they can become sites of
non-specific binding, increasing the background of an affinity experiment. A
commercially available resin from Pharmacia Biotech is CH-Sepharose 4B (Figure 4).
A major drawback to the covalent attachment of NACP to Sepharose is the
location of the lysines in the protein sequence; most of the lysines are clustered in
the N-terminal repeat region. If the binding site is in the region, binding proteins
will most likely not be isolated.
There are two general methods for performing the chromatography: column
or batch19. Unlike the column method, the batch method can be done on a very
small scale. It is a useful way of beginning affinity experiments.
Recombinant NACP (purified by boiling) was fixed to CNBr-activated
Sepharose 4B. The substitution level was approximately 18 g NACP/mg beads.
Control beads were generated in the same fashion with lysozyme as the ligand.
Lysozyme was chosen because the protein is similar in molecular weight to NACP,
and is very inexpensive. In addition, NACP was attached to activated CH-Sepharose
413 at a substitution level of 20 pg NACP/mg beads. Lastly, beads with a low
substitution of NACP was prepared, at a level of 4 pg NACP/mg beads. Controls
(beads substituted with lysozyme) were generated for both sets of beads. Substitution
levels of the beads were estimated by examining the concentration of uncoupled
protein in the coupling washes.
Rat brain cytosol (from Liu lab) was incubated with the high substitution-
CNBr beads, after which they were isolated via centrifugation. The beads were
washed in one of two ways: 1) with lysis buffer; or 2) with lysis buffer, and then with
buffers of increasing salt concentration. The beads were then boiled in 1 x SDS gel
loading buffer and run on polyacrylamide gel. Candidate proteins were difficult to
identify due to the high background of the gels. Repeated washings to reduce the
background of the gels did not help.
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Even if a candidate protein is identified, it is necessary to show that the
protein can be released from the beads by washing with the ligand (NACP).
Competition experiments were performed on the beads, yet no candidate proteins
were identified, again due to high background.
The same set of experiments was performed with the other sets of beads.
Although high background was not a problem with these beads, no candidate
proteins were seen on these gels.
There is the possibility that the binding protein of NACP is membrane
associated. Bovine brain membrane fractions were obtained from the Liu lab and
experiments were performed with all three sets of beads. No proteins were
identified.
High background difficulties can possibly be avoided by performing these
experiments in a column, and repeatedly passing large amounts of homogenate
through the column. The column may become saturated with proteins of interest,
thereby reducing the high background of these experiments. It is also possible that
these experiments are inherently flawed: NACP is attached to the Sepharose
through the lysines contained in the repeat region of the N-terminus. If binding
occurs there, these experiments will not identify any ligands.
The C-terminus of NACP contains many carboxylic acid groups, which can be
used for attachment to the Sepharose. Unfortunately, all commercial preparations
of such beads are based upon amide bond formation, between an amino group on
the resin and an activated carboxylic acid group. NACP has many lysines; it would
be very difficult to prevent oligomers of NACP from forming during the activation
procedure.
Affinity chromatography with recombinant NACP may not be an appropriate
method for discovering binding proteins. Native NACP may have a post-
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translational modification which is critical for ligand binding. For this reason,
immunoprecipitation from rat brain homogenate may be a better technique.
Immunoprecipitation
An alternative technique to affinity chromatography for finding a protein's
ligand is immunoprecipitation 2 1 . In this technique, an antibody to NACP would be
allowed to bind to NACP in rat brain homogenate. If the antibody is polyclonal, a
large number of antibody molecules may bind to the protein; the antibody-NACP
combination may precipitate and can be collected by centrifugation. The use of a
mixture of monoclonal antibodies, specific for different epitopes, can also cause
immunoprecipitation. It is hoped that any protein bound to NACP would also be
precipitated in the process, thus isolating any ligands of NACP. Only tight binding
ligands will likely be isolated.
The monoclonal antibody H3C (mouse IgG1) was provided by David Clayton
in the form of reconstituted mouse ascites8 . It is an antibody to the canary C
terminal sequence YEMPPEEEYQDYEPEA. The rat C terminal sequence only differs
by two amino acids (YEMPSEEGYQDYEPEA), and is recognized by the H3C antibody
(Figure 6). Because the antibody is specific to the C-terminus of NACP, we can
investigate the possibility that the N-terminus is involved in ligand binding; this
was not possible with the affinity chromatography experiments.
This antibody was thus used as the primary antibody in all immunoprecip-
itation experiments. Monoclonal antibodies are usually not desirable for immuno-
precipitation because only one antibody molecule can bind to each NACP molecule.
Isolation of the antibody-NACP complex is achieved through one of two methods:
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1) an excess of polyclonal antibody, specific to the primary antibody, is added; or 2)
Protein A-Sepharose or Protein G-Sepharose is added.
Protein A and Protein G are cell wall proteins of specific bacteria which bind
to the constant region (Fc) of antibodies 2l. The two proteins have different affinities
for antibodies, depending upon their species and subclass. Protein G has a higher
affinity for mouse IgG1, and was the reasonable choice for precipitating agent.
Because Protein G contains a second binding site which will bind to albumin,
GammaBind Plus Sepharose (Pharmacia Biotech) was used in all experiments.
Gammabind Plus Sepharose has been engineered to not bind to albumin. Albumin
binding is undesirable, because the background of any experiment would be
heightened.
The cytosolic protein of rat frontal cortex consists of as much as 0.5% - 1% of
NACP11. Ten stripped whole rat brains were homogenized and separated into
cytosolic and membrane fractions. The cytosolic total protein concentration of
prepared rat brain cytosol was 6.8 mg/mL as assayed by BCA. Estimating that the rat
frontal cortex consists of 25% of the total rat brain mass, it was estimated that
between 100 pg and 200 g of H3C per mL rat brain cytosol was necessary for efficient
immunoprecipitation. Through analyzing Western blots, it was estimated that the
concentration of H3C ascites was approximately 100 mg/mL, but could range
between 40-200 mg/mL. Through these calculations, the quantity of antibody
required per mL of rat brain cytosol was estimated.
3 il of H3C was used per mL of rat brain cytosol in order to form the 1°
antibody - NACP - ligand complex. 50 1 of Protein G beads were added (beads have
an antibody capacity of 18 mg/ml) to isolate the complex. The beads were boiled in 1
X SDS loading buffer to generate sample G1. In order to control for nonspecific
binding, two controls were run. Rat brain cytosol was incubated with Protein G
beads (control 1 beads, C1); this controls for nonspecific binding to the Protein G
29
beads. To control for nonspecific binding to the constant regions of IgG1 and to
control for proteins contained in mouse ascites, rat brain cytosol was incubated with
mouse monoclonal ca-Neurofilament 200 (Sigma, ascites), before isolation with
Protein G beads (control 2 beads, C2). a-Neurofilament 200 was chosen as a control
antibody, because it is an mouse IgG1 against a common brain protein.
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Figure 5. 12 % polyacrylamide gel. Lanes: 1, recombinant NACP; 2, experimental
G:L; 3, control C1; 4, control C2; 5, antibody H3C; 6, rat brain cytosol. Comparison of
lane 2 with 3-6 show that a doublet band (arrows) at MW 19 and 20 kDa is selectively
immunoprecipitated in G1.
Comparison of lane 2 (G1) against lanes 3, and 4 (C1, C2), and 5 (H3C) show
that a doublet 19 and 20 kDa protein is specifically precipitated when the H3C
antibody is used (Figure 5). The bottom band runs at the same level as recombinant
NACP; Western blotting with H3C as the 1 antibody shows that the doublet band is
specifically recognized by H3C (Figure 6, lane 2). Iwai, et al. also noted that their
antibodies to NACP recognized a doublet band in both human and rat homo-
genates". They speculate that the higher molecular weight is NACP with a post-
translational modification. However, post-translationally modified human NACP
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has previously been observed to comigrate with recombinant NACP4 . It is unlikely
that the higher molecular weight band is either rat synuclein 2 or 3, because they do
not contain the proper epitope. The high molecular weight band may be an as-yet-
undiscovered alternatively spliced form of rat synuclein 1.
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Figure 6. Western blot analysis, detected with anti-NACP monoclonal antibody
H3C. Lanes: 1, recombinant NACP; 2, experimental G1; 3, experimental IP1; 4, rat
brain cytosol. Arrows indicate doublet band of NACP.
Examination of a 7% acrylamide gel (Figure 7) shows that, in lane 2 (G1) there
is a band at approximately 96 kDa which does not exist in any control lanes (3, 4, and
5). By Western blotting, this 96 kDa protein does not react with the H3C antibody
(Figure 6). Interestingly, Nakajo, et al. perform an immunoprecipitation with
polyclonal -PNP-14, and coprecipitated two proteins along with PNP-14: an 82 kDa
protein, and a 96 kDa protein5 . The 96 kDa protein may therefore be an NACP
binding protein.
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Figure 7. A 7% polyacrylamide gel. Lanes: 1, recombinant NACP; 2, experimental
G1; 3, control C1; 4, control C2; 5, antibody H3C; 6, experimental IP1. Comparison of
lanes 3-5 with lane 2 show that a 96 kDa protein (arrow) was selectively immuno-
precipitated in G1.
If a different method than Protein G was used to isolate the complex, and the
96 kDa protein was again isolated, the 96 kDa protein would be a viable candidate
ligand. Isolating the 96 kDa protein in two different ways would reduce the
likelihood that the protein is non-specifically binding to the Protein G beads.
Immunoprecipitation, therefore, using an excess of goat a-mouse IgG to precipitate
the H3C-NACP-ligand complex was attempted. Rat brain cytosol was incubated with
H3C, after which, an excess of goat a-mouse IgG was added (estimated to be 15 fold
excess). White precipitate formed, which was pelletted and isolated. The pellet was
dissolved in 1 X SDS gel loading buffer, to generate sample IP1. Attempts to achieve
good resolution on the gels was not successful. The high concentration of IgG
relative to all other proteins caused streaking (Figure 5, lane 6), making it impossible
to ascertain the presence or absence of a 96 kDa band. Western blotting, however,
indicated that NACP was precipitated (Figure 6, lane 3).
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In order to identify the 96 kDa protein, G1 was electrophoresed on a 6%
acrylamide gel. The separated proteins were blotted onto PVDF, and the membrane
was stained with Commassie Blue R-250. The 96 kDa protein was submitted for N-
terminal amino acid sequencing.
Future Experiments
If a sequence is obtained from the immunoblot, then the protein may be
identified from a search of the protein sequence data banks. Whether the protein is
identified, or is an unknown protein, we must prove that the immunoprecipitation
of the 96 kDa protein is not simply an artifact. Probably the best way to do this is to
make an antibody to the 96 kDa protein, and immunoprecipitate the 96 kDa protein
out of rat brain cytosol. If NACP is co-precipitated with the 96 kDa protein, then we
can put more confidence into the designation of the protein as an NACP-binding
protein. Polyclonal antibodies can be made easily: the protein can be purified by
SDS-polyacrylamide gel electrophoresis and injected into rabbits.
Another experiment which must be performed is the identification of the
post-translational modification of NACP. Small amounts of NACP can be purified
from rat brain cytosol by performing an immunoprecipitation, and isolating the
doublet NACP from the rat cytosol. The NACP can be purified in the immuno-
globulins by separating the mixture on SDS-polyacrylamide gels and blotting onto
PVDF. The NACP doublet can be isolated, and eluted separately from the mem-
brane. The quantities obtained from a membrane should be adequate for mass
spectrometry. In addition a tryptic digest can be performed, and the site of the post-
translational modification can be identified from the molecular weight of the
fragments.
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Experimental Section
IEquipment. Materials, and Methods
All chemicals and materials were purchased from Sigma unless otherwise
noted. Rat brains were obtained from Pelfreez. BL21(DE3) competent cells were
purchased from Novagen. Monoclonal ca-NACP H3C was obtained from David
Clayton. The plasmid containing the NACP expression vector was obtained from
Michel Goedert. All beads for affinity chromatography, gel filtration, ion-exchange,
and immunoprecipitation were purchased from Pharmacia Biotech.
Gel Electrophoresis
Polyacrylamide gels were poured and run according to the method of
Laemmli2 2. Native gels were poured and run according to established methods23 .
All gels were visualized by Commassie Blue R-250. All gels were run in a Novex
mini-cell system.
Western Blotting
Proteins were electrophoresed on SDS-polyacrylamide gels then blotted onto
PVDF in a TE 70 SemiPhor Semi-Dry Transfer Unit. The proteins were transferred
according to established procedure24. The proteins were transferred at 100 mA for 45
min. Prestained molecular weight markers were always run in the gel to check the
efficiency of transfer. After the transfer, the membrane was incubated with blocking
buffer (1% BSA in 50 mM Tris, 150 mM NaCl, pH 7.5) for 15 min. The membrane
was then incubated with primary antibody (H3C, 1:100,000 dilution) in blocking
buffer for 2 h. The membrane was washed with washing buffer (50 mM Tris, 150
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mM NaCi, pH 7.5) for 1 x 1 min, 3 x 5 min, and then incubated with secondary
antibody (goat anti-mouse IgG conjugated to alkaline phosphatase, Sigma A-1682,
1:4000) in blocking buffer for 1 hour. The membrane was again washed with
washing buffer (1 x 1 min, 3 x 5 min). The membrane was developed with a
solution of BCIP/NBT (Sigma Fast BCIP/NBT, B-5655). Staining for total protein on
membranes was done with Commassie Blue R-250.
Expression of NACP
A pRK172 plasmid containing the NACP expression sequence4. was dissolved
in TE and added to 25 ll of competent BL21(DE3) cells. The cells were stored on ice
for 30 min, heat shocked at 42 C for 30 s, then let sit at RT for 2 min. 500 P1 of Luria-
Bertani Broth (LB) containing 0.2% glucose was prewarmed to 37°C and added to the
cells. After incubation at 37 C for 1 h, 200 1il of the bacteria were plated onto
ampicillin positive agar plates25. The bacteria was grown for 17 h at 37'C. Control
plate (competent cells without the plasmid) did not grow colonies. Two colonies
were chosen. Each colony was used to inoculate a stab culture25, which was grown
for 36 h and stored at -80°C. All cultures were henceforth grown from stab culture
A.
10 mL of LB, containing 100 g/mL of ampicillin, was inoculated from stab
culture A, and shaken at 37°C for 12 h. 2 x 500 mL of LB (with 50 Ctg/mL ampicillin)
were each inoculated with 5 mL of the culture. The 500 mL cultures were grown at
37°C until absorption equaled 0.6-1.0 at 600 nm (blanked against LB). The cultures
were induced with isopropyl-1-thio-p-galactoside (IPTG) to a final concentration of
0.5 mM, and shaken for 2 h at 37C. The cultures were centrifuged at 11,000 x g for 30
min. The cells were frozen in dry ice-acetone and stored at -20°C.
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Purification of NACP from E. coli
The frozen cells were thawed at 4'C, and resuspended in working buffer (WB,
50 mM Tris-HCl, 0.1 mM DTT, 0.1 mM PMSF, pH 7.4). The cells were lysed in a
french press at 16,000 psi. The lysate was centrifuged at 14,000 x g for 30 min. The
supernatant was removed, and streptomycin sulfate was added (0.2 volumes of 5%
streptomycin sulfate in working buffer). After stirring on ice for 15 min, the lysate
was centrifuged at 24,000 x g for 30 min. The supernatant was removed and heated
in a boiling water bath for 10 min. The boiled lysate was centrifuged at 24,000 x g for
30 min. The supernatant was loaded onto a 25 g of Biogel P-10 and eluted with WB.
The protein eluted in the void volume, but was acceptably pure to use.
Purification of NACP from E. coli Without Boiling Step
The frozen cells were thawed, lysed, and treated with streptomycin sulfate as
above. Ammonium sulfate was added to 46.6% saturation and stirred 1 h at 4 C.
The suspension was centrifuged at 10,000 x g for 10 min. The pellet was resuspended
in WB and loaded onto a gel filtration column (S-300). NACP was eluted with
working buffer; Ve/Vo approximately equaled 1.5. All fractions containing NACP
(assayed by gel electrophoresis) were combined; the concentration of the WB was
increased to 100 mM Tris, and 50 mM NaCl. The fractions were loaded onto 40 mL
of CL-6B DEAE Sepharose gel and eluted with a NaCl gradient (50 mM to 312 mM
NaC1, over 300 mL). NACP eluted at approximately 200 mM NaCl. All fractions
containing NACP were combined and dialyzed against distilled H20 (24 h, 2 changes
of H20). The fractions were frozen in dry ice/acetone, lyophilized, and stored at
-,''0 C.
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Ferguson plots
Native gels were poured of 6%, 10% and 14% acrylamide concentration. BSA
(68 kDa), pepsin (35 kDa), insulin (5.7 kDa), and NACP (14.5 kDa) were dissolved in
1X native gel loading buffer and run on each gel.
Preparation of Affinity Beads of High Protein Substitution
250 mg of cyanogen bromide (CNBr) activated Sepharose 4B were washed,
over a fritted funnel, with 50 mL of 1 mM HC1. The gel was washed with 1.25 mL of
coupling buffer (100 mM NaHCO3, 500 mM NaCl, pH 8.3), then immediately added
to a solution of 0.42 pmol of protein (NACP or lysozyme) in 2 mL of coupling buffer.
The gel was rotated slowly at 4°C for 21 h. The beads were filtered and washed with
2 mL of coupling buffer. Approximate concentration of uncoupled protein in the
filtrate was assayed by UV. The gel was resuspended in 3 mL of blocking buffer (100
mM NaHCO3, 500 mM NaCl, 200 mM glycine, pH 8.0) and rotated at room
temperature for 2 h. The beads were washed alternately, 4 or 5 times, with coupling
buffer and acetate buffer (100 mM NaOAc, pH 4). The beads were washed with PBS
(50 mM potassium phosphate, 500 mM NaCl, pH 7.2) and stored at 4C in 1 mL PBS
(total volume approximately 1.8 mL).
Preparation of CH-Sepharose 4B Based Affinity Beads
100 mg of activated CH-Sepharose 4B were washed with 10 mL of 1 mM cold
HCl over a fritted funnel. The beads were washed with 200 l of coupling buffer
(100 mM NaHCO3, 500 mM NaCl, pH 8.0), then added to 0.16 pmol of protein
(N]ACP or lysozyme) in 200 i1l of coupling buffer. The beads were rotated for 1 h at
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RT, then filtered and washed with coupling buffer. Approximate concentration of
uncoupled protein in the filtrate was assayed by UV. The beads were blocked with
Tris-HCl buffer (100 mM Tris, 500 mM NaCl, pH 8.0) and rotated for 1 h at RT. The
beads were filtered and washed alternately, 5 times, with Tris-HCl buffer then acetate
buffer (100 mM, pH 4). The resin was stored in 400 pl of Tris buffer (20 mM Tris, 100
rmM NaCl, 2 mM DTT, pH 6.3).
Preparation of Affinity Beads of Low Protein Substitution
50 mg of CNBr activated Sepharose 4B was washed with 10 mL of 1 mM HC1,
followed by 1 mL of coupling buffer (100 mM NaHCO3, 500 mM NaCl, pH 8.3). The
beads were added to 0.5 mL of coupling buffer and rotated. After 5 h, 0.024 kumol of
protein (NACP or lysozyme) in 200 l of coupling buffer was added to the beads.
After 16 h, the beads were filtered and washed with coupling buffer. Approximate
concentration of uncoupled protein in the filtrate was assayed by UV. The gel was
resuspended in blocking buffer (100 mM NaHCO3, 500 mM NaCl, 200 mM glycine,
pHI 8.0) and rotated at room temperature for 2 h. The resin was stored in 200 pl of
Tris buffer (20 mM Tris, 100 mM NaCl, 2 mM DTT, pH 6.3).
Affinity Experiments with Rat Brain Cytosol
100 p1 of bead slurry (experimental or control) was placed into 1.5 mL
microfuge tubes and washed 4 times with Tris buffer (20 mM Tris, 100 mM NaCl, 2
mM DTT, pH 6.3) by centrifuging and removing the supernatant. 800 1l of rat brain
cytosolic extract (1 mg/mL) was added and the tubes were rotated at 4C for 4 h. The
tubes were centrifuged and supernatant removed (control supernatant (CS) and
experimental supernatant (ES)). Beads were washed in one of three different ways:
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1) washed once with Tris buffer; 2) washed successively with Tris buffer of
increasing salt concentration (100 mM, 200 mM, 300 mM); or 3) washed once with
Tris buffer, then twice with a 5 mg/mL solution of lysozyme or NACP. Beads
(control beads (CB) and experimental beads (EB)) were boiled in 100 l of 1X SDS gel
loading buffer.
Preparation of Membrane Fraction for Affinity Experiments
1 mL of bovine brain membrane fraction (10-12 mg/mL total protein, gift of
Liu lab) was washed with 6 mL of buffer (25 mM Tris, 50 mM KC1, 5 mM MgCl, 1
mM EDTA, pH 7.4) and centrifuged at 108,000 x g in a T-100 mini ultracentrifuge for
1 h at 4C. The pelleted membrane was resuspended in 6 mL of buffer containing
0.32% Triton X100 and 1 mM PMSF. The suspension was homogenized with 10
strokes of a Dounce homogenizer, after which, it was rotated at 4C for 4 h. The
suspension was centrifuged at 108,000 x g for 1 h at 4C. The concentration of the
supernatant was 0.8 mg/mL total protein assayed by BSA. The supernatant was used
for affinity chromatography experiments.
Affinity Experiments with Bovine Brain Membrane Fractions
150 gl of bead slurry (experimental or control) was placed into 1.5 mL
m-Licrofuge tubes and washed 4 x with solubilization buffer (25 mM Tris, 50 mM KC1,
5 mM MgCl, 1 mM EDTA, 0.32% Triton X100 , 1 mM PMSF, pH 7.4). 800 gl of
bovine brain membrane extract was added and the tubes were rotated at 4°C for 4 h.
The tubes were centrifuged and supernatant removed (control supernatant (CS) and
experimental supernatant (ES)). Beads were washed as described above. Beads were
boiled in 50 1ll of 1X SDS gel loading buffer.
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P:reparation of Rat Brain Cytosol and Membrane Fractions
Twenty grams of stripped rat brains (10 brains) were thawed at 4°C in 80 mL
of homogenization buffer (50 mM Tris-HCl, 1 mM EDTA, 0.1 mM PMSF, 0.1 mM
DTT, pH 7.4). Each brain was diced with a clean razor blade in a petri dish lined with
parafilm. The rat brains were homogenized with a Polytron, twice for 30 s on setting
5. The suspension was centrifuged at 800 x g for 15 min. The supernatant was
centrifuged at 100,000 x g for 1 h. The clear supernatant was removed with a pipette.
5'2 mL of supernatant was recovered. The concentration of rat brain cytosol was 6.8
mg/mL as determined by BCA. Glycerol was added to the supernatant to a final
concentration of 5%. The supernatant was aliquotted in 1 mL fractions. The
membrane fraction was resuspended in homogenization buffer (18 mL). Glycerol
was added to a final concentration of 5% and aliquotted into 1 mL fractions. All
fractions were frozen in dry ice/acetone, and stored at -80°C.
Immunoprecipitation with Protein G Beads
Monoclonal antibody (H3C, mouse IgG1) to NACP was obtained from David
Clayton8. Rat brain cytosol was thawed at 4C. 1.35 ipl of H3C was added to the 500 pl
of cytosol, and it was incubated at 4C for 2 h. 50 u1l of a 1:1 slurry of GammaBind
Plus Sepharose was washed twice with homogenization buffer (50 mM Tris-HCl, 1
mM EDTA, 0.1 mM PMSF, 0.1 mM DTT, pH 7.4); the beads were then added to the
rat brain cytosol, and incubated, with rotation, for 1 h. The beads were centrifuged
and washed 3 times with 150 ,1 of homogenization buffer. The beads were boiled in
50 ,1 of lx SDS gel loading buffer. Two sets of controls were also generated: instead
of H3C, either 13.9 1 of monoclonal -NF200 (Sigma, IgG1, N-0142) or nothing was
added.
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Immunoprecipitation With Goat anti Mouse IgG
250 1 of rat brain cytosol was treated with 6.75 lI of a 1:10 dilution of H3C.
After incubating for 4 h, 1 mL of a 1 mg/mL solution of a goat ca-mouse IgG (Sigma,
M-8642) was added. The solution was incubated overnight, after which a white
precipitate could be seen in the tube. The suspension was centrifuged in a
microfuge, and the supernatant was removed. The pellet was washed twice with 1
mL of homogenization buffer (50 mM Tris-HCl, 1 mM EDTA, 0.1 mM PMSF, 0.1
mM DTT, pH 7.4). The pellet was dissolved in 50 ll of 1 x SDS gel loading buffer.
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